Nearly a third of all drugs approved in the last decade by the U.S. Food and Drug Administration subsequently had "postmarket safety events," which included boxed warnings, safety communications and/or withdrawal of the products, according to a study by researchers at the Yale School of Medicine published on the American Medical Association's JAMA Network.
Among 222 "novel therapeutics" approved by the FDA from 2001 through 2010, 32 percent were affected by a postmarket safety event, according to the study. Biologics, psychiatric therapeutics, and accelerated and near–regulatory deadline approval were statistically significantly associated with higher rates of events.
"Postmarket safety events are common after FDA approval, highlighting the importance of continuous monitoring of the safety of novel therapeutics throughout their life cycle," the authors wrote.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
